HIV drug under review as firm withdraws FDA applicationBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7341.807/a (Published 06 April 2002) Cite this as: BMJ 2002;324:807
- Pat Sidley
South Africa's already confused and controversial policy on HIV and AIDS was plunged into further disagreement last week as the German pharmaceutical manufacturer Boehringer Ingelheim announced that it would withdraw its application to the US Food and Drug Administration for its antiretroviral drug nevirapine to be registered in the United States for use in preventing HIV transmission from mother to child.
The drug has been registered for use in adults and children with HIV and AIDS, but in South Africa it has received registration only for use in reducing the risk of HIV transmission from mother to child. Now South Africa's drug …